dr perlmutter glutathione Randomized, double‐blind, pilot evaluation of intravenous in Parkinson's disease - Hauser - 2009 - Movement Disorders Dr. David Perlmutter explains why

These represent fundamentally different biological scenarios even though both involve the same molecular players

The purchaser accepts full responsibility for lawful handling, storage, and application of this material

Patients may read about thymosin beta-4 wound-healing studies and assume the same conclusions apply directly to commercially marketed TB-500 products

However, BPC 157 remains experimental and is not FDA-approved for human medical use

The case for stacking BPC-157 and TB-500 comes down to this: they work on different phases through different mechanisms, so combining them addresses more of the healing cascade than either alone